Trial Profile
Phase 1, multiple, ascending-dose study of BIIB033 in patients with relapsing-remitting multiple sclerosis (RRMS) or secondary-progressive multiple sclerosis (SPMS)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Apr 2014
Price :
$35
*
At a glance
- Drugs Opicinumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Sponsors Biogen Idec
- 28 Apr 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
- 23 Apr 2014 New trial record